logo
Plus   Neg
Share
Email

XFOR Prices Offering At $12/Shr

X4 Pharmaceuticals, Inc. (XFOR) plans to sell 3.66 million shares of its common stock at $12 per share. The gross proceeds from the offering are expected to be approximately $65.0 million. The offering is slated to close on or about November 29, 2019.

Cowen and Stifel are acting as joint book-running managers for this offering.

Canaccord Genuity and Oppenheimer & Co. are acting as lead managers, and H.C. Wainwright & Co. and Roth Capital Partners are acting as managers for the offering.

X4 Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases.

The lead drug candidate is Mavorixafor.

A pivotal Phase 3 clinical trial of Mavorixafor for the treatment of WHIM syndrome is underway. The 52-week trial is designed to enroll 18 to 28 subjects in
approximately 20 countries, followed by an open-label extension trial.

Mavorixafor is also being explored in other indications like Severe Congenital Neutropenia and advanced clear cell renal cell carcinoma. The Company is also in preparations to begin Phase 1b clinical trial of Mavorixafor in Waldenström's macroglobulinemia later this quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Beverages giant Coca Cola said it has no plans to abandon single-use plastic bottles as its consumers still want to use them. Bea Perez, Coca-Cola's senior vice president for sustainability, told the BBC at the World Economic Forum in Davos that consumers like the single-use plastic bottles as they reseal and are lightweight. The Procter & Gamble Company (PG) reported that its second-quarter core earnings per share rose 14 percent year-on-year, due to lower non-core restructuring charges versus the prior year. Currency-neutral core earnings per share increased 15 percent. Organic sales were up five percent, for the quarter.... While reporting financial results for the fourth quarter on Thursday, JetBlue Airways Corp. (JBLU) provided its financial outlook for the first quarter and the full-year 2020. For the first quarter, the company expects earnings in a range of $0.10 to $0.20 per share. Capacity is expected to increase...
RELATED NEWS
Follow RTT
>